Effect of Respiratory Muscle Training in Interstitial Lung Patients

Status Active, not recruiting

Clinical Trial Summary

The aim of this study is to investigate the possible effects of inspiratory muscle training (IMT) on respiratory functions, functional capacity, balance and quality of life in patients with interstitial lung disease.

Clinical Trial Description

Interstitial lung disease (ILD) include a heterogeneous group of progressive, acute and chronic diseases that diffusely affect the lung and characterized by varying degrees of inflammation and fibrosis in the lung parenchyma. The disease group usually shows a restrictive pattern and progresses with gas exchange abnormalities. Progressive lung fibrosis was first described in 1935. Over the years, more than 150 lung disease characterized by acute or chronic pulmonary fibrosis of varying degrees with known or unknown cause have been defined and these diseases were named interstitial lung disease (ILD) in 1970s. Common symptoms in chronic interstitial lung diseases in general; dyspnea, dry cough, exercise intolerance and fatigue. All these features of interstitial lung diseases cause an increase in respiratory work and ventilatory deterioration in exercise. Apart from these general features, muscle weakness and related exercise intolerance may occur in some specific conditions. The most important factor limiting exercise capacity in these patients is circulatory disorder, which cause exercise induced deterioration in gas exchange. Hypoxemia induced exercise intolerance causes a decrease in health-related quality of life, limitation of functional capacity and inactivity in daily life. According to the American Thoracic Society (ATS) / European Respiratory Society (ERS) respiratory rehabilitation guideline, although the data are not conclusive, inspiratory muscle training is recommended as an adjunct to pulmonary rehabilitation, especially in patients with suspected or confirmed respiratory muscle weakness. The effect of well-structured and supervised inspiratory muscle training (IMT) on respiratory functions, diaphragm weakness, functional capacity, balance and quality of life in patients with interstitial lung disease is unknown. It is important that this research will be carried out in this area and because it has a current subject. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05106556
Study type	Interventional
Source	Bezmialem Vakif University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	December 9, 2019
Completion date	January 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04905693` - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	Phase 3
Recruiting	`NCT05631132` - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?	N/A
Recruiting	`NCT05417776` - Collagen-targeted PET Imaging for Early Interstitial Lung Disease	Phase 2
Not yet recruiting	`NCT04089826` - Long Term Oxygen Therapy in Patients With Interstitial Lung Disease
Recruiting	`NCT03467880` - Multicenter Study of Impulse Oscillometry in Chinese	N/A
Completed	`NCT00883129` - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)	Phase 2
Completed	`NCT00362739` - Blood Collection From Individuals With Lung Disease for Genetic Studies	N/A
Recruiting	`NCT06133998` - Effects of Incentive Spirometry With and Without Aerobic Exercises in Interstitial Lung Disease	N/A
Active, not recruiting	`NCT03485378` - Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease	N/A
Recruiting	`NCT04098094` - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting	`NCT03400839` - Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases
Terminated	`NCT02633293` - An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE	Phase 2/Phase 3
Enrolling by invitation	`NCT05001009` - Goals of Care Conversations Study	N/A
Active, not recruiting	`NCT05068869` - Digital Outpatient Services	N/A
Active, not recruiting	`NCT03727568` - Study Comparing Two Different Methods of Cryobiopsy in the Interstitial Lung Diseases	N/A
Recruiting	`NCT06046547` - Integrating Palliative Care Education in Pulmonary Rehabilitation	N/A
Completed	`NCT04946708` - Virtual Exercise Program in Interstitial Lung Disease (ILD) Patients	N/A
Recruiting	`NCT04139356` - The Effect of Spontaneous Respiration on Pulse-oximetry Measurements	N/A
Recruiting	`NCT03726398` - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH	Phase 2/Phase 3
Active, not recruiting	`NCT03295279` - WTC Chest CT Imaging Archive

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.